Page last updated: 2024-12-07
3-amino-1,2,4-benzotriazine-1-oxide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-amino-1,2,4-benzotriazine-1-oxide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 79470 |
| CHEMBL ID | 461345 |
| SCHEMBL ID | 1651160 |
| SCHEMBL ID | 11856691 |
| MeSH ID | M0177092 |
Synonyms (26)
| Synonym |
|---|
| 1,2,4-benzotriazin-3-amine 1-oxide |
| nsc-13158 |
| nsc13158 |
| 5424-06-6 |
| 3-amino-1,2,4-benzotriazine 1-oxide |
| CHEMBL461345 |
| 3-aminobenzo[e][1,2,4]triazine 1-oxide |
| 1-oxido-1,2,4-benzotriazin-1-ium-3-amine |
| AKOS004121499 |
| STK792842 |
| 3-amino-1,2,4-benzotriazine-1-oxide |
| 3-amino-1,2,4-benzotriazin-1-ium-1-olate |
| AB1028 |
| AB01330536-02 |
| 3-amino-1,2,4-benzotriazine-1-n-oxide |
| MB00333 |
| SCHEMBL1651160 |
| BBRWGJRKAHEZBG-UHFFFAOYSA-N |
| 1,2,4-benzotriazine-3-amine 1-oxide |
| SCHEMBL11856691 |
| mfcd00024038 |
| DTXSID30202590 |
| NCGC00336762-01 |
| TQP0606 |
| 3-aminobenzo[e][1,2,4]triazine1-oxide |
| 1-oxy-benzo[1,2,4]triazin-3-ylamine |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "133 mmol/kg) significantly enhanced hypoxic cell killing in HT29 tumor xenografts without causing oxic cell killing, and the combination at its maximum tolerated dose was less toxic to hypoxic cells in the retina than was TPZ alone at its maximum tolerated dose." | ( Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Brown, JM; Hay, MP; Hogg, A; Pruijn, FB; Siim, BG; Sturman, JR; Wilson, WR, 2004) | 0.32 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " These small species differences in protein binding are unlikely to have any major impact on the extrapolation of pharmacokinetic data from mice to humans." | ( Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation. Graham, MA; Robin, H; Senan, S; Workman, P, 1995) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID409716 | Cytotoxicity against mouse EMT6/KU cells in aerobic condition for 5 hrs measured after 7 to 10 days | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors. |
| AID409717 | Cytotoxicity against mouse EMT6/KU cells in hypoxic condition for 5 hrs measured after 7 to 10 days | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors. |
| AID409715 | Inhibition of indoleamine 2,3-dioxygenase in aerobic condition | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (69.23) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||